EVONETIX

In News

Evonetix raises $30m for desktop gene synthesis tech - drugdiscoverytrends.com

drugdiscoverytrends.com - Mar 02, 2020

Evonetix Announces Agreement for Revolutionary Gene Synthesis Platform with Analog Devices - Business Wire

Business Wire - Dec 06, 2023

Gene-length DNA synthesis for scaling engineering biology - BioTechniques

BioTechniques - Nov 03, 2023

Cambridge University receives first synthesized DNA from Evonetix - PharmaTimes

PharmaTimes - May 10, 2023

Back to the future as Diston takes CEO role in Evonetix rebuild - Business Weekly

Business Weekly - Mar 12, 2024

Synthetic biology gets a makeover with Evonetix’s DNA synthesis technology - SynBioBeta

SynBioBeta - Jul 08, 2019

Evonetix Appoints Colin McCracken as Chief Executive Officer - Technology Networks

Technology Networks - Jun 13, 2022

ADI and Evonetix developing a DNA desktop writer - Electronics Weekly

Electronics Weekly - Sep 10, 2020

Evonetix Closes $24 Million USD (£20 Million) Financing - Business Wire

Business Wire - Feb 07, 2023

The Long and Winding Road: On-Demand DNA Synthesis in High Demand - Genetic Engineering and Biotechnology News

Genetic Engineering and Biotechnology News - Jul 27, 2023

Evonetix raises £9m for novel gene synthesis tech - PharmaTimes

PharmaTimes - Jan 30, 2018

Evonetix expands facilities and relocates to central Cambridge, UK - SynBioBeta

SynBioBeta - Oct 30, 2019

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment